Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Poziotinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 20/20 | 1.00 |
| ▸ | ERBB2 known ✓ | P04626 | 5/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | RET | P07949 | 1/20 | 1.00 |
| ▸ | MET | P08581 | 1/20 | 1.00 |
| ▸ | EPHB2 | P29323 | 1/20 | 1.00 |
| ▸ | TEC | P42680 | 1/20 | 1.00 |
| ▸ | EPHB4 | P54760 | 1/20 | 1.00 |
| ▸ | EPHA4 | P54764 | 1/20 | 1.00 |
| ▸ | BTK | Q06187 | 1/20 | 1.00 |
| ▸ | TNK1 | Q13470 | 1/20 | 1.00 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Poziotinib SCHEMBL3391764 | 1.00 | EGFR (1.00) | EGFRERBB2KCNH2RIPK2RET | |
| Poziotinib SCHEMBL29453260 | 1.00 | EGFR (1.00) | EGFRERBB2KCNH2RIPK2RET | |
| Poziotinib SCHEMBL14841985 | 0.99 | EGFR (0.98) | EGFRERBB2KCNH2RIPK2RET | |
| SCHEMBL22598558 | 0.95 | EGFR (1.00) | EGFRERBB2KCNH2RIPK2RET | |
| SCHEMBL29751974 | 0.95 | EGFR (1.00) | EGFRERBB2KCNH2RIPK2RET | |
| SCHEMBL3390837 | 0.95 | EGFR (1.00) | EGFRERBB2KCNH2RIPK2RET | |
| SCHEMBL14786610 | 0.94 | EGFR (0.88) | EGFRERBB2KCNH2RIPK2RET | |
| SCHEMBL3391925 | 0.94 | EGFR (1.00) | EGFRERBB2KCNH2RIPK2RET | |
| SCHEMBL21613670 | 0.93 | EGFR (0.87) | EGFRERBB2KCNH2RIPK2RET | |
| SCHEMBL29444156 | 0.93 | EGFR (1.00) | EGFRERBB2KCNH2RIPK2RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595297-B2 | Methods and compositions for inhibition of EGF/EGFR pathway in combination with tyrosine kinase inhibitors | IN3BIO LTD. (BM) | 2026-04-07 | — | — | US | claimed |
| US-20240269136-A1 | EGFR INHIBITOR AND PERK ACTIVATOR IN COMBINATION THERAPY AND THEIR USE FOR TREATING CANCER | GENENTECH, INC. (US) | 2024-08-15 | — | — | US | claimed |
| EP-4392423-A1 | QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE | Arthrosi Therapeutics, Inc. (US) | 2024-07-03 | — | — | EP | claimed |
| EP-4355330-A1 | EGFR INHIBITOR AND PERK ACTIVATOR IN COMBINATION THERAPY AND THEIR USE FOR TREATING CANCER | Genentech, Inc. (US) | 2024-04-24 | — | — | EP | claimed |
| CN-117479943-A | EGFR inhibitors and PERK activators in combination therapies and use thereof for treating cancer | 基因泰克公司 | 2024-01-30 | — | — | CN | claimed |
| WO-2023028054-A1 | QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE | ARTHROSI THERAPEUTICS, INC. (US) | 2023-03-02 | — | — | WO | claimed |
| WO-2022265950-A1 | EGFR INHIBITOR AND PERK ACTIVATOR IN COMBINATION THERAPY AND THEIR USE FOR TREATING CANCER | GENENTECH, INC. (US) | 2022-12-22 | — | — | WO | claimed |
| CN-122074043-A | Combination therapy with KRAS modulators | 光达治疗公司 | 2026-05-22 | — | — | CN | disclosed |
| US-20250243171-A1 | QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE | ARTHROSI THERAPEUTICS, INC. | 2025-07-31 | — | — | US | disclosed |
| WO-2025106901-A1 | COMBINATION CANCER THERAPIES WITH A KRAS MODULATOR AND AN RTK-MAPK PATHWAY INHIBITOR | QUANTA THERAPEUTICS, INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| WO-2025034919-A1 | COMBINATION THERAPIES WITH KRAS MODULATORS | QUANTA THERAPEUTICS, INC. (US) | 2025-02-13 | — | — | WO | disclosed |
| US-20240269136-A1 | EGFR INHIBITOR AND PERK ACTIVATOR IN COMBINATION THERAPY AND THEIR USE FOR TREATING CANCER | GENENTECH, INC. (US) | 2024-08-15 | — | — | US | disclosed |
| EP-4412717-A1 | COMBINATION THERAPIES OF KRAS G12D INHIBITORS WITH PAN ERBB FAMILY INHIBITORS | Mirati Therapeutics, Inc. (US) | 2024-08-14 | — | — | EP | disclosed |
| EP-4017495-A1 | POZIOTINIB COMBINATION WITH VEGFR2 INHIBITORS AND METHODS OF USE THEREOF | Spectrum Pharmaceuticals, Inc. (US) | 2022-06-29 | — | — | EP | disclosed |
| US-11365189-B2 | Heterocyclic inhibitors of tyrosine kinase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-06-21 | — | — | US | disclosed |
| WO-2022043923-A1 | SYNTHESIS OF POZIOTINIB DERIVATIVE | HANMI SCIENCE CO., LTD. (KR) | 2022-03-03 | — | — | WO | disclosed |
| EP-3956035-A1 | COMPOUNDS AGAINST CANCER BEARING TYROSINE KINASE INHIBITOR RESISTANT EGFR MUTATIONS | Board of Regents, The University of Texas System (US) | 2022-02-23 | — | — | EP | disclosed |
| EP-3946632-A1 | COMPOUNDS WITH ANTI-TUMOR ACTIVITY AGAINST CANCER CELLS BEARING HER2 EXON 21 INSERTIONS | Board of Regents, The University of Texas System (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3946293-A1 | COMPOUNDS WITH ANTI-TUMOR ACTIVITY AGAINST CANCER CELLS BEARING EGFR OR HER2 EXON 20 INSERTIONS | Board of Regents, The University of Texas System (US) | 2022-02-09 | — | — | EP | disclosed |
| WO-2022026442-A1 | TREATMENT OF NON-SMALL CELL LUNG CANCER WITH POZIOTINIB | SPECTRUM PHARMACEUTICALS, INC. (US) | 2022-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250243171-A1 | QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE | EGFR, ABL1, ERBB2 | EGFR 1/4885ERBB2 3/4885KCNH2 3824/4885 |
| US-12595297-B2 | Methods and compositions for inhibition of EGF/EGFR pathway in combination with tyrosine kinase inhibitors | EGFR, ERBB2, ERBB3 | EGFR 1/4885ERBB2 2/4885KCNH2 3216/4885 |
| US-20240269136-A1 | EGFR INHIBITOR AND PERK ACTIVATOR IN COMBINATION THERAPY AND THEIR USE FOR TREATING CANCER | EGFR, ERBB2, ERBB4 | EGFR 1/4885ERBB2 2/4885KCNH2 4876/4885 |
| US-11365189-B2 | Heterocyclic inhibitors of tyrosine kinase | ERBB2, ERBB3, EGFR | EGFR 3/4885ERBB2 1/4885KCNH2 4678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.